
Oncolytic Molecules that Kill Cancer with Direct & Abscopal Tumor Effects
Neoadjuvant Immunotherapy with Durable Responses Approaching Registrational Studies
Our Pipeline is Led by Ruxotemitide, Rapidly Approaching Registrational Studies
Asset
Preclinical
Phase I
Phase II
Phase III
Partner
Ruxotemitide (LTX-315)
Neoadjuvant resectable melanoma
Seeking Partners
LTX-401
Deep-seated solid tumors
Seeking Partners
More Pipeline Assets...
Ruxotemitide (LTX-315)
Neoadjuvant resectable melanoma
Seeking Partners
PreIIIIII
LTX-401
Deep-seated solid tumors
Seeking Partners
PreIIIIII
More Pipeline Assets...
News
Latest Press Releases
Nov 17, 2026
Lytix Biopharma ASA: Ex. subsequent offering
Lytix Biopharma ASA: Ex. subsequent offering
Read MoreNov 17, 2026
Lytix Biopharma ASA: Key information relating to the subsequent offering
Lytix Biopharma ASA: Key information relating to the subsequent offering
Read MoreNov 17, 2026
Lytix Biopharma ASA - Mandatory notification of trade by close associates to primary insiders
Lytix Biopharma ASA - Mandatory notification of trade by close associates to primary insiders
Read More




